Administration of bispecific antibodies that bind to surface molecules expressed on cDCs (e.g., DNGR‐1, CD40, PD‐L1) and T cells (e.g., PD‐1, CD40L, CD28) enhances cDC‐T physical interactions, restoring anti‐tumour immunity in animal models [135, 136, 137, 138, 139]. The gene discussed is CLEC9A; the disease is neoplasm.